



## CAGRISEMA BLEND 10mg (Cagrilintide 5mg/Semaglutide 5mg) For Weight Loss

Our Product Introduction

for more products please visit us on [peptide-powder.com](http://peptide-powder.com)

### Basic Information

- Place of Origin: China
- Brand Name: Hongbaiyi
- Certification: COA, HPLC MR
- Model Number: HBY-Cagrisema
- Minimum Order Quantity: 5 boxes
- Price: negotiable
- Packaging Details: 10mg/vial, 10vials/box
- Delivery Time: 3-5 work days after your payment
- Payment Terms: MoneyGram, Western Union, T/T
- Supply Ability: 20,000 boxes/month



### Product Specification

- Name: Cagrisema Weight Loss
- CAS No.: 910463-68-2
- Molecular Formula: C187H291N45O59
- Molecular Weight: 4114
- Storage Temp: Peptides Should Be Stored In A Dry, Cool, Dark Place. For Best Preservation, Store At 4°C Or Colder Away From Bright Light.
- Specification: 10mg/vials, 10vials /box



### More Images



### Product Description



Carglisema (cargliptin/semaglutide) is a combination of cargliptin, a dual agonist of starch and calcitonin receptors, and semaglutide, a GLP-1 agonist. It is an effective long-term combination therapy for the treatment of type 2 diabetes and obesity.

Results from clinical trials of Cargrisema have shown that it exhibits superior results in weight loss and blood glucose reduction compared to cagliptin or semaglutide alone. In addition, Cargrisema significantly reduced patients' glycated hemoglobin (HbA1c) levels.

There are many peptide-based weight loss products on the market today, and HBY can offer these products and accept customizations as well:

Product Name	CAS Number	Availability
Semaglutide	910463-68-2	√
Tirzepatide	2023788-19-2	√
Retatrutide	2381089-83-2	√
Cagrilintide	1415456-99-3	√
Dulaglutide	923950-08-7	√
Cargrisema	Cagrilintide+Semaglutide	√
Liraglutide	204656-20-2	√
Survodutide	2805997-46-8	√
Ecnoglutide	2459531-73-6	√
Mazdutide	2259884-03-0	√

#### How does Cargrisema work?

Cargrisema is a novel dual-action therapy designed to effectively treat type 2 diabetes and obesity by combining semaglutide and cagrilintide, two complementary pharmaceutical ingredients.

Semaglutide is a long-acting GLP-1 receptor agonist that mimics the action of the natural gut hormone GLP-1, slowing digestion, enhancing satiety, and lowering blood sugar by increasing glucose-dependent insulin secretion. Cagliflozin peptide is a long-acting amyloid peptide analog with dual agonism that acts on amyloid peptide and calcitonin receptors, mimicking the effects of the amyloid peptide to further promote satiety and reduce intestinal sensitivity. Sugar absorption. Therefore, it may enhance the weight loss effects of Semaglutide.

Carglisema is unique in that it combines the strengths of both Semarutide and Cargliptin peptides to form a powerful combination therapy. Semaglutide starts with blood sugar control, reducing sugar intake and absorption. Cagliptin starts by regulating appetite, reducing food intake, and increasing energy expenditure. This two-pronged mechanism allows Cagliflozin to provide a more comprehensive treatment for patients with type 2 diabetes and obesity.

#### 3. What are the potential benefits of Cargrisema?

**Effective in controlling blood glucose:** Cargrisema has shown significant efficacy in lowering blood glucose levels in clinical trials. the Trifecta trial demonstrated that Cargrisema significantly lowered HbA1c levels by 1.8% compared to placebo, and in the DURATION-6 trial, Cargrisema lowered HbA1c by 1.7% compared to dulaglutide. This shows that Carglisema significantly reduces HbA1c levels, which is a key indicator of long-term glycemic control.













**Significant weight loss:** The dual mechanism of action of Carglisema reduces body weight by decreasing appetite and increasing satiety and energy expenditure. In the STEP obesity trial, carglima resulted in an average weight loss of 12.1% compared to placebo and significantly improved cardiometabolic markers. In the RESET-O trial, carglisema resulted in an average weight loss of 16.4% and significant reductions in body fat percentage and waist circumference compared to placebo.















**Improved Cardiovascular Health:** The positive effects of carglisema on glycemic and weight control may also translate into improved cardiovascular health. Studies have shown that Cargresem lowers blood pressure, improves blood lipids, and reduces the risk of cardiovascular events.

#### Product Images:



**Shipping:**

 <span>132763</span>  成功签收 (9 天)	美国 FedEx — 美国	2024-05-01 14:38 US, AZ, Tucson, Delivered, Left at front door. Signature Service not requested.
签收时间: 2024-05-01		
 <span>4262</span>  成功签收 (7 天)	美国 FedEx — 美国	2024-04-30 14:27 US, CA, San Diego, Delivered, Left in locker/storage. Signature Service not requested.
签收时间: 2024-04-30		
 <span>15317</span>  成功签收 (9 天)	美国 FedEx — 美国	2024-05-02 18:16 US, TX, Waxahachie, Delivered, Left at front door. Signature Service not requested.
签收时间: 2024-05-02		
 <span>4148</span>  成功签收 (9 天)	美国 FedEx — 美国	2024-05-02 18:16 US, TX, Waxahachie, Delivered, Left at front door. Signature Service not requested.
签收时间: 2024-05-02		
 <span>1707</span>  成功签收 (9 天)	美国 FedEx — 美国	2024-05-02 18:16 US, TX, Waxahachie, Delivered, Left at front door. Signature Service not requested.
签收时间: 2024-05-02		
 <span>5144</span>  成功签收 (9 天)	美国 FedEx — 美国	2024-05-02 18:16 US, TX, Waxahachie, Delivered, Left at front door. Signature Service not requested.
签收时间: 2024-05-02		

	1ZX1101X0490517859  成功签收 (7 天)	香港 [CN] UPS	→ 美国	2024-04-29 11:07 PHILADELPHIA, PA, US
<b>接收时间：2024-04-29</b>				
	1ZX1101X0491958069  成功签收 (7 天)	香港 [CN] UPS	→ 美国	2024-04-29 13:58 PHILADELPHIA, PA, US
<b>接收时间：2024-04-29</b>				
	1ZX1101X0493619396  成功签收 (8 天)	香港 [CN] UPS	→ 美国	2024-04-29 13:58 PHILADELPHIA, PA, US
<b>接收时间：2024-04-29</b>				
	1ZX1101X0498335853  成功签收 (7 天)	  香港 [CN] UPS	→ 美国	2024-04-29 13:58 PHILADELPHIA, PA, US
<b>接收时间：2024-04-29</b>				
	1ZX1101X0490338801  成功签收 (8 天)	香港 [CN] UPS	→ 美国	2024-04-29 11:07 PHILADELPHIA, PA, US
<b>接收时间：2024-04-29</b>				
	1ZX1101X0491082782  成功签收 (8 天)	香港 [CN] UPS	→ 美国	2024-04-29 13:58 PHILADELPHIA, PA, US
<b>接收时间：2024-04-29</b>				

**3rd Lab report:**

# TEST REPORT



E-mail: [info@janoshik.com](mailto:info@janoshik.com)  
Web: [www.janoshik.com](http://www.janoshik.com)

Task Number #42875

Testing ordered > 20 MAY '24

Sample received > 27 MAY '24

Client

Sample

Manufacturer

Batch

CAGRISEMA 10

solutionpeptides.com

051

Sample description >

Pictures not included.

Tests requested >

Assessment of a peptide vial or vials.

Results >

Cagrilintide	5.25 mg
Semaglutide	5.36 mg

Comments >

Analysis conducted > 29 MAY 2024

Signature >

Verify this test at [www.janoshik.com/verify/](http://www.janoshik.com/verify/) with the following unique key



Shaanxi Hongbaiyi Biotech Co., Ltd.

18192109180

[tracy@sxhongbaiyi.com](mailto:tracy@sxhongbaiyi.com)

[peptide-powder.com](http://peptide-powder.com)

Hengjia Business Building, No.115 Weiyang Road, E&T Development Zone, Xi'an, Shaanxi, China.